Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Stroke

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Antiplatelet drug vs control

Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke

It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).

1 finding from 1 review

Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
Peto OR 1.18 [0.97, 1.44]
9 studies · 41652 participants
Very low

Anticoagulant vs control

Symptomatic intracranial haemorrhage during treatment period · acute presumed ischaemic stroke

Summary of findings table ‐ Anticoagulant probably leads to higher symptomatic intracranial haemorrhage during treatment period compared with control (moderate certainty).

1 finding from 1 review

Anticoagulants for acute ischaemic stroke 2021 · Cochrane Headline outcomes only
OR 2.47 [1.9, 3.21]
21 studies · 23221 participants
Moderate

Low‐molecular‐weight heparins or heparinoids vs unfractionated heparin

Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period (range 6 days to 16 days)⁹ · acute ischaemic stroke

Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke 2017 · Cochrane Headline outcomes only
OR 0.73 [0.35, 1.54]
8 studies · 3102 participants
Low